Category: Replacement Heart ValvesSyndicate content

Heart Valves

Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup

September 17, 2014 by Arezu Sarvestani

Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.

TCT 2014 Roundup

Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.

Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.

TCT 2014: Boston Scientific's 1-year data on Lotus TAVI device

September 16, 2014 by Brad Perriello

Boston Scientific's Lotus replacement heart valve shows low leakage rates and no instances of moderate or severe leakage, a problem that plagued the earlier generation of transcatheter aortic valve implants.

TCT 2014: Boston Scientific's 1-year data on Lotus TAVI device

TCT 2014: TAVI takes center stage

September 15, 2014 by Brad Perriello

Transcatheter aortic valve implants take center stage at the annual Transcatheter Cardiovascular Therapeutics conference with the latest data dumps from rivals Medtronic and Edwards Lifesciences.

TCT 2014: TAVI takes center stage

St. Jude Medical hits 'pause' on Portico TAVI device

September 15, 2014 by Brad Perriello

St. Jude Medical hits 'pause' on implantations of its Portico replacement heart valve after CT scans turned up a potential problem with the devices.

St. Jude Medical hits 'pause' on Portico TAVI trial

Stealthy mitral valve maker emerges at TCT 2014 | MassDevice.com On Call

September 15, 2014 by Arezu Sarvestani

After more than 10 years underground, MVRx unveils its mitral valve repair system during the Transcatheter Cardiovascular Therapeutics conference.

MassDevice.com On Call

MASSDEVICE ON CALL — Bad timing and a financial crisis nearly buried MVRx and its mitral valve repair technology forever, but the company's founders finally revealed their progress over the weekend at the Transcatheter Cardiovascular Therapeutics conference.

TAVI: Symetis battles the big dogs

September 15, 2014 by Arezu Sarvestani

Symetis has been battling Medtronic and Edwards Lifesciences for years in the European transcatheter aortic valve implantation market, and the company's aiming to squeeze out Boston Scientific, St. Jude Medical and other major players in the U.S.

Symetics battles the big dogs in TAVI

Switzerland-based medical implant maker Symetis is looking to make some major moves in the global transcatheter aortic valve implantation market, and the company's not afraid to take on some of the medtech industry's biggest players.

Press Release: Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system

September 12, 2014 by MassDevice

Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for Transcatheter Aortic Heart Valve Delivery

Press Release: Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system

LAUSANNE, SWITZERLAND - Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of ACURATE neo, its 15F compatible transfemoral TAVI system. Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp